Tango Therapeutics (TNGX) stock price is $25.25, up 7.31% on the day, as of Oct 20, 2026. It has a market cap of $3.79Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap3.79 Bn
P/E-30.64
P/S70.44
Div. Yield0.00
Add ratio to table…
About
Tango Therapeutics Inc is a biotechnology company focused on discovering and developing targeted oncology therapies. The company uses synthetic lethality approaches to create drugs that selectively kill cancer cells with specific genetic alterations while sparing normal cells. Its pipeline includes small molecule inhibitors that target methyltransferase PRMT5, the CoREST complex, and the HBS1L protein.
The company currently generates revenue through collaboration and…
Tango Therapeutics Inc is a biotechnology company focused on discovering and developing targeted oncology therapies. The company uses synthetic lethality approaches to create drugs that selectively kill cancer cells with specific genetic alterations while sparing normal cells. Its pipeline includes small molecule inhibitors that target methyltransferase PRMT5, the CoREST complex, and the HBS1L protein.
The company currently generates revenue through collaboration and licensing agreements with other pharmaceutical firms. These partnerships provide funding for research development and potential milestone payments. Tango Therapeutics does not yet have commercial product sales.
Tango Therapeutics occupies a niche in the oncology market by focusing on synthetic lethality and biomarker driven patient selection. Its main competitors include large pharmaceutical companies such as AstraZeneca Amgen Bristol Myers Squibb Gilead GlaxoSmithKline Merck KGaA Pfizer Lilly and Roche as well as smaller biotechs like Artios Pharma BeOne Exelixis IDEAYA Biosciences Repare Therapeutics and Servier Pharmaceuticals. The company's competitive advantages stem from its proprietary MTA cooperative mechanism for PRMT5 inhibition its deep understanding of genetic deficiencies and its ability to pair drug candidates with specific patient populations.
The company serves oncology patients who have tumors with defined genetic alterations such as MTAP deletion. Its collaboration partners include Erasca Revolution Medicines and Lilly which provide compound supplies and support clinical trials. These relationships help advance the development of its product candidates toward potential regulatory approval.
Sector:HealthcareSector rationaleTango Therapeutics is a biotechnology company that discovers and develops targeted oncology therapies, specifically small molecule inhibitors for cancer cells. Its revenue model is based on collaboration and licensing agreements with pharmaceutical firms to fund the research and development of these medical products.Industry:BiotechnologyBiotechnologyPrimaryTango Therapeutics is a biotechnology company that researches and develops therapies derived from biological science, specifically using synthetic lethality to target cancer cells. Its revenue is currently derived from collaboration and licensing agreements with pharmaceutical firms, which is a characteristic revenue model for clinical-stage biotech developers.Classified using BQ-MICSCIK: 0001819133
Bull & bear
Investment Thesis
▲ Bull case
Tango Therapeutics is positioned to capitalize on a significant unmet medical need in pancreatic cancer, a disease with notoriously low survival rates and limited effective treatment options, where the company's experimental drug combination demonstrated strong early efficacy signals in a small but promising study. The positive data, which led to a 45% premarket share surge, suggests the therapy may overcome key resistance mechanisms in this historically treatment-resistant indication, potentially offering a meaningful improvement over current standards of care. Management's stated intention to advance the treatment into late-stage testing reflects confidence in the data's robustness and regulatory viability, which could de-risk the path to approval if pivotal trials confirm the initial signal. Given the high cost burden and poor prognosis associated with pancreatic adenocarcinoma, any therapy showing meaningful clinical benefit could command premium pricing and rapid adoption, especially if it demonstrates a favorable safety profile in broader populations. The market may be underestimating the strategic value of this asset beyond pancreatic cancer, as the underlying mechanism—potentially targeting DNA damage response or synthetic lethality pathways—could have applicability in other solid tumors with similar genomic profiles, creating optionality for pipeline expansion. Furthermore, the early-stage success may attract partnership interest from larger oncology-focused pharmaceutical companies seeking to bolster their late-stage assets, providing non-dilutive funding and validation that could accelerate development timelines. If Tango can successfully transition from early proof-of-concept to pivotal trials without significant setbacks, the company could redefine its valuation trajectory from a speculative biotech to a near-term commercialization candidate in a high-value niche.
Tango Therapeutics is positioned to capitalize on a significant unmet medical need in pancreatic cancer, a disease with notoriously low survival rates and limited effective treatment options, where the company's experimental drug combination demonstrated strong early efficacy signals in a small but promising study. The positive data, which led to a 45% premarket share surge, suggests the therapy may overcome key resistance mechanisms in this historically treatment-resistant indication, potentially offering a meaningful improvement over current standards of care. Management's stated intention to advance the treatment into late-stage testing reflects confidence in the data's robustness and regulatory viability, which could de-risk the path to approval if pivotal trials confirm the initial signal. Given the high cost burden and poor prognosis associated with pancreatic adenocarcinoma, any therapy showing meaningful clinical benefit could command premium pricing and rapid adoption, especially if it demonstrates a favorable safety profile in broader populations. The market may be underestimating the strategic value of this asset beyond pancreatic cancer, as the underlying mechanism—potentially targeting DNA damage response or synthetic lethality pathways—could have applicability in other solid tumors with similar genomic profiles, creating optionality for pipeline expansion. Furthermore, the early-stage success may attract partnership interest from larger oncology-focused pharmaceutical companies seeking to bolster their late-stage assets, providing non-dilutive funding and validation that could accelerate development timelines. If Tango can successfully transition from early proof-of-concept to pivotal trials without significant setbacks, the company could redefine its valuation trajectory from a speculative biotech to a near-term commercialization candidate in a high-value niche.
Tango Therapeutics faces substantial execution risks in advancing its pancreatic cancer drug combination into late-stage testing, as the transition from small early-phase studies to pivotal trials is notoriously fraught with failure due to issues like inadequate patient selection, unanticipated toxicities, or failure to replicate efficacy in larger, more diverse populations. The company's reliance on a single clinical asset—particularly one targeting a historically challenging indication like pancreatic cancer—creates significant binary risk, where any negative or inconclusive result in upcoming trials could severely impair investor confidence and trigger a sharp valuation correction, especially given the lack of diversified pipeline assets to buffer such setbacks. Management did not disclose detailed safety data from the early study, raising concerns about potential dose-limiting toxicities or manageability issues that could hinder widespread adoption even if efficacy is confirmed, particularly in elderly or comorbid patients who constitute the majority of pancreatic cancer cases. The 45% premarket share surge following the news may reflect excessive short-term optimism that discounts the high failure rates inherent in pancreatic cancer therapeutics, where numerous promising candidates have failed in late-stage trials despite strong preclinical or early clinical signals. Additionally, Tango's financial runway and ability to fund expensive late-stage trials independently remain unclear from the provided context, raising the prospect of dilutive financing or unfavorable partnership terms that could erode shareholder value if external capital is required. Without clear differentiation from existing or emerging competitors in the pancreatic cancer space—such as other immunotherapy combinations, targeted KRAS inhibitors, or novel chemotherapies—the company may struggle to secure a meaningful market share even upon approval, limiting long-term commercial upside.
Tango Therapeutics faces substantial execution risks in advancing its pancreatic cancer drug combination into late-stage testing, as the transition from small early-phase studies to pivotal trials is notoriously fraught with failure due to issues like inadequate patient selection, unanticipated toxicities, or failure to replicate efficacy in larger, more diverse populations. The company's reliance on a single clinical asset—particularly one targeting a historically challenging indication like pancreatic cancer—creates significant binary risk, where any negative or inconclusive result in upcoming trials could severely impair investor confidence and trigger a sharp valuation correction, especially given the lack of diversified pipeline assets to buffer such setbacks. Management did not disclose detailed safety data from the early study, raising concerns about potential dose-limiting toxicities or manageability issues that could hinder widespread adoption even if efficacy is confirmed, particularly in elderly or comorbid patients who constitute the majority of pancreatic cancer cases. The 45% premarket share surge following the news may reflect excessive short-term optimism that discounts the high failure rates inherent in pancreatic cancer therapeutics, where numerous promising candidates have failed in late-stage trials despite strong preclinical or early clinical signals. Additionally, Tango's financial runway and ability to fund expensive late-stage trials independently remain unclear from the provided context, raising the prospect of dilutive financing or unfavorable partnership terms that could erode shareholder value if external capital is required. Without clear differentiation from existing or emerging competitors in the pancreatic cancer space—such as other immunotherapy combinations, targeted KRAS inhibitors, or novel chemotherapies—the company may struggle to secure a meaningful market share even upon approval, limiting long-term commercial upside.